These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 7898101)

  • 1. Nilvadipine: profile of a new calcium antagonist. An overview.
    Rosenthal J
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist.
    Honerjäger P; Seibel K
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S15-21. PubMed ID: 1283184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of nilvadipine.
    von Nieciecki A; Huber HJ; Stanislaus F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-hour blood pressure control after single daily doses of nivaldipine in patients with essential hypertension.
    Lossnitzer K; Huber HJ; Kuchlbauer R; Quitzdorff G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S35-42. PubMed ID: 1283187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nilvadipine on the cardiovascular system in experimental animals.
    Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T
    Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amlodipine: a once daily calcium antagonist.
    Burges RA
    J Hum Hypertens; 1991 Aug; 5 Suppl 1():49-54. PubMed ID: 1834846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilvadipine in hypertension with renal dysfunction.
    Berger HH; Albert FW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S73-9. PubMed ID: 1283194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
    Brogden RN; McTavish D
    Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
    Leonetti G;
    Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension.
    Faust G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S56-61. PubMed ID: 1283191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.
    van Zwieten PA; Pfaffendorf M
    J Hypertens Suppl; 1993 Dec; 11(6):S3-8. PubMed ID: 8169379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension.
    Maier-Lenz H; Rode H; Lenau H; Thieme G; Wölke E; Kobayashi H; Kobayashi S; Oka T
    Arzneimittelforschung; 1988 Nov; 38(11A):1757-63. PubMed ID: 3219156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacological properties of lipophilic calcium antagonists.
    van Zwieten PA
    Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate.
    Yamaura T; Kase N; Kita H; Uematsu T
    Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
    Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
    Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in rats.
    Karasawa A; Kubo K; Shuto K; Oka T; Nakamizo N
    Arzneimittelforschung; 1988 Nov; 38(11A):1684-90. PubMed ID: 3064752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of nilvadipine and nitrendipine on circadian blood pressure.
    Keck M
    J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S43-9. PubMed ID: 1283188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect].
    Heynen G
    Schweiz Rundsch Med Prax; 1992 Feb; 81(7):199-203. PubMed ID: 1531545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.